Silencing Programmed-Death Ligands in a dendritic cell vaccine to improve tumor-reactive T cell and NK cell responses University of Antwerp
Given their potential to stimulate both adaptive and innate anti-tumor immune responses, dendritic cells (DCs) are subject of intense examination as pharmacological tools for cancer immunotherapy. A growing body of evidence indicates that DC vaccination can be of clinical benefit to cancer patients, encouraging the further development of this therapy. Nevertheless, there is a general agreement among cancer researchers that the true clinical ...